P01: Long-term survival after surgical treatment of thymic carcinoma
Poster Session

P01: Long-term survival after surgical treatment of thymic carcinoma

Ke-Neng Chen1, Hao Fu1, Zhitao Gu2, Wentao Fang2, Hua J. Fu3, Yi Shen4, Yong-Tao Han5, Zhen-Tao Yu6, Yin Li7, Li-Jie Tan8, Liewen Pang9

1Department of Thoracic Surgery, Beijing Cancer Hospital, Beijing 100142, China; 2Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai 200231, China; 3Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; 4Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao 266005, China; 5Department of Thoracic Surgery, The Second People’s Hospital of Sichuan, Chengdu 610041, China; 6Department of Thoracic Surgery, Tianjin Medical University Cancer Institute, Tianjin 300060, China; 7Department of Thoracic Surgery, The Correlation Analysis Thymoma Pathological Staging and Prognosis, Zhengzhou 450008, China; 8Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 9Department of Cardiothoracic, Huashan Hospital, Shanghai 200040, China


Background: Thymic carcinoma is a type of highly malignant tumor that originates from the thymic epithelium. It is rare and distinct from thymoma. Treatment methods and prognosis of thymic carcinoma remain controversial. To date, three studies with relatively large sample populations have been conducted based respectively on the Surveillance, Epidemiology and End Results database in the United States, the European Society of Thoracic Surgeons, and the Japanese multicenter database. This paper retrospectively analyzes survival data from a large-sample multicenter database in China.

Methods: The Chinese Alliance for Research of Thymoma (ChART) constructed a retrospective database of patients with thymic epithelial tumors, which enrolled 2,421 patients from January 1992 to December 2013, including 364 with thymic carcinomas. In this study, we analyzed clinical, pathologic and treatment information, measured long-term survival rates, and identified relevant prognostic factors.

Results: Of 364 patients, R0 resection was performed in 235 cases (64.6%), R1 in 42 cases (11.5%), and R2 in 87 cases (23.9%). The 3-, 5-, and 10-year survival rates were 79.8%, 69.0%, and 48.5%, respectively. The survival rates of the patients at different Masaoka-Koga stages were significantly different (P<0.001). The survival rate of the patients who underwent complete resection (R0) was higher than that with incomplete resection (R1/R2), and the difference was statistically significant (P<0.001). Postoperative chemotherapy did not significantly affect patient survival (P=0.808). Postoperative radiotherapy significantly improved the overall survival not only of the patients with R1/R2 resection but also of those with stage III/IV disease who underwent R0 resection (P=0.003). Multivariate analyses showed that R0 resection, postoperative radiotherapy and Masaoka-Koga Stage were major prognostic factors of thymic carcinoma.

Conclusions: Complete resection is the preferred primary treatment for thymic carcinoma. R0 resection, early Masaoka-Koga stage and postoperative radiotherapy are significant predictors of improved survival.

Keywords: Thymic tumors; thymic carcinoma; staging; prognostic factors


doi: 10.3978/j.issn.2072-1439.2015.AB070


Cite this abstract as: Chen KN, Fu H, Gu Z, Fang W, Fu HJ, Shen Y, Han YT, Yu ZT, Li Y, Tan LJ, Pang L. P01: Long-term survival after surgical treatment of thymic carcinoma. J Thorac Dis 2015;7(Suppl 3):AB070. doi: 10.3978/j.issn.2072-1439.2015.AB070

Article Options

Download Citation